Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma.
Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma.
复制标题
血清胸苷激酶作为多发性骨髓瘤患者疾病活动的标志物。
DOI：
10.1111/j.1445-5994.1989.tb00251.x
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
H. Kronenberg
中科院分区：
文献类型：
--
作者：
Ross D. Brown;R. Ioannidis;D. Joshua;H. Kronenberg
血清胸苷激酶（STK）水平最近已被用来检测肿瘤的退化和进展的血液恶性肿瘤。在这项研究中，对骨髓瘤患者的STK和其他几种潜在有用的肿瘤标志物进行了纵向监测，以确定哪些实验室参数对区分稳定和进展性疾病最有用。STK测定采用放射酶法，淋巴细胞表面标志物测定采用流式细胞术，浆细胞标记指数（LI）测定采用抗BU-1免疫荧光法，血清B_2-微球蛋白（SB_2 M）测定采用放射免疫法，M蛋白测定采用放射免疫扩散法。5例患者的详细多参数纵向研究和70例其他患者的正在进行的研究表明，STK是比SB 2 M，LI，M蛋白或CD 10阳性淋巴细胞更可靠的疾病进展标志物。在疾病进展期间，STK的升高至少持续3个月，并且通常在其他参数的任何变化之前，而这些参数通常根本没有变化。来自患有进展性疾病的患者（n = 29）的所有样品具有高于正常范围（0- 5 U/l）的STK，而76%的处于明确稳定疾病的患者具有在正常范围内的STK。所有轻链同种型抑制（LCIS）患者的样本（n = 34）的STK值均小于12 U/L，82%的无LCIS患者样本（n = 33）的STK值高于正常范围（0- 5 U/L）。STK与LI之间的相关性为r = 0.65; p <0.001（n = 21）。STK的放射酶测定法简单、可重复，是监测骨髓瘤患者的一种有价值的工具，当与其他临床和实验室研究结合使用时，有助于将稳定型骨髓瘤患者与疾病进展的患者分开。
Serum thymidine kinase (STK) levels have recently been used to detect tumour regression and progression in a number of hematological malignancies. In this study, patients with myeloma were monitored longitudinally for STK and several other potentially useful tumour markers to determine which laboratory parameters are the most useful for differentiating between stable and progressive disease. STK was determined by radioenzyme assay, lymphocyte surface markers were analysed by flowcytometry, plasma cell labelling index (LI) by immunofluorescence with anti BU-1, serum B2-microglobulin (SB2M) by radioimmunoassay and M proteins by radial immunodiffusion. Detailed multiparameter longitudinal investigations of 5 patients and ongoing studies of 70 other patients suggest that STK is a more reliable marker of progressive disease than either SB2M, LI, M-protein or CD10 positive lymphocytes. A rise in STK during the emergence of progressive disease at least paralleled and usually preceded any change in the other parameters which often did not change at all. All samples from patients with progressive disease (n = 29) had a STK above the normal range (0-5U/l) whereas 76% of patients in clear stable disease had a STK within the normal range. All samples (n = 34) from patients with light chain isotype suppression (LCIS) had STK values of less than 12 U/L and 82% of samples (n = 33) from patients without LCIS had a STK above the normal range (0-5U/L). The correlation between STK and LI was r = 0.65; p less than 0.001 (n = 21). The radioenzyme assay for STK is simple, reproducible and a valuable tool for monitoring patients with myeloma and when used in conjunction with other clinical and laboratory investigations, aids in the separation of patients with stable myeloma from patients whose disease is progressive.
骨髓瘤的免疫调节回路。
DOI：
--
发表时间：
1982
期刊：
Clinics in haematology
影响因子：
--
作者：
Ullrich,S;Zolla-Pazner,S
通讯作者：
Zolla-Pazner,S